Dividend Aristocrats, S&P 500 companies that have increased payouts for 25 or more consecutive years, remain the foundation of income portfolios through the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine operating on all cylinders, and a home improvement company priced for a home improvement that hasn’t quite arrived. Each pick offers a verified payout, a forward-looking thesis, and a clear risk to weigh.
McDonald’s (NYSE: MCD)
McDonald’s (NYSE:MCD | mcd price prediction) Right now there is the classic “buy weakness” setup. On Monday, July 6, shares traded around $275, down more than 9% year to date and more than 6% over the past year. That poor performance has pushed the yield on the annual payout of $7.26 per share to 2.71%.
The dividend record is the anchor. Alpha Vantage data confirms an unbroken quarterly dividend history from 1999 to 2026, with the most recent jump from $1.77 to $1.86 per share. McDonald’s has raised its payout for decades while comfortably clearing the aristocrat bar.
Operationally, the business is working. Q1 2026 delivered EPS of $2.83 versus an estimated $2.74, revenue of $6.52 billion (up 9% YoY), and global comparable sales up 4%. CEO Chris Kempczinski said, “McDonald’s performed well this quarter. Our 6% global systemwide sales growth reflects how we acted with discipline.” Spending on food services in the broader economy supports the setup: PCE data shows food services expanded steadily from January to $1,538.3 billion in May 2026.
risk: Margin pressure may increase from inflationary cost pressures, tariffs and intense QSR competition. A Forward P/E of 21 isn’t cheap if comp growth stops.
AbbVie (NYSE: ABBV)
AbbVie (NYSE:ABBV) The name of this trio is speed. The stock is up 14% in the last month, 11% year-to-date and 36% in the past year. The yield on the annualized payout of $6.74 per share works out to be 2.71%.
A note on the Aristocrat label: AbbVie’s standalone dividend streak spans 12 consecutive years (2013 to 2026) since its spin-off from Abbott Laboratories on January 1, 2013. Counting the combined Abbott lineage gets you to the traditional 25-year range, but on a standalone basis, it’s a 12-year streak that has seen quarterly payments increase from $0.40 to $0.40. $1.73.
Growth Engine has completely replaced Humira. Q1 2026 revenue reached $15 billion (up 12% year-over-year), with Skyrizi at $4.48 billion (+31%) and Rinvoke at $2.12 billion (+23%). Management raised 2026 adjusted EPS guidance to $14.08-$14.28. CEO Robert A. Michael said AbbVie “has made an excellent start to 2026, with first-quarter results exceeding our expectations.”
risk: The degradation of Humira biosimilars remains brutal, with the franchise declining 50% in FY2015, and negative shareholders’ equity on the balance sheet. After the recent rally, the valuation has been increased on a trailing basis.
Lowe’s (NYSE: LOW)
Lowe’s (NYSE: LOW) It is a contradictory choice. Shares traded around $221.95 on Monday, July 6, down 10% year-to-date despite a nearly 7% surge in the past month. The quarterly dividend has just increased to $1.25, with the next date being July 22.
The streak is real aristocrat material. AlphaVantage data shows steady year-over-year dividend increases from 1999 to 2026, with the Q2 payout rising from 3 cents in 1999 to $1.20 in 2026.
The thesis housing lock-in depends on trade. Current home sales in May 2026 stood at 4.17M year-on-year, still below the healthy 4.5-5.5M band. This keeps homeowners in their place and encourages renovation spending. Furnishing PCE has increased from $516.7 billion in January to $531.6 billion in May 2026. Q1 FY2027 results showed that revenue grew 10% year-on-year to $23.08 billion, the fourth consecutive positive quarter, and online sales grew 16%. CEO Marvin R. Ellison cited “strong spring execution and continued momentum across pro, tools, online and home services.” FY2026 guidance calls for adjusted diluted EPS of $12.25-$12.75.
risk: Housing starts fell 15% month-over-month to 1.177 million units in May, a warning that demand for new construction is slowing. With margin erosion from recent acquisitions and tariff exposure, the recovery may take longer than bulls expect.
ground level
These three names cover different macro lanes: McDonald’s offers value at a discount and global QSR exposure, AbbVie offers growth-driven earnings momentum, and Lowe’s lets investors lean into the home improvement cycle while collecting rising payouts. For income investors making the July watchlist, the combination of yield, growth and verified dividend track records make each worth a closer look.
Contact (email protected) For any questions or corrections.